Vertex Signs Gene Editing Partnership with Verve for US$466 M

By Swati Sharan

Pharma Deals Review: Vol 2022 Issue 7 (Table of Contents)

Published: 29 Jul-2022

DOI: 10.3833/pdr.v2022.i7.2709     ISSN: 1756-7874

Section: Licensing



In a bid to broaden its gene editing capabilities, Vertex Pharmaceuticals has entered into a four-year global research collaboration agreement with Verve Therapeutics...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details